Immune responses associated with homologous protection conferred by commercial vaccines for control of avian pathogenic Escherichia coli in turkeys

Simple item page
dc.contributor.authorSadeyen, Jean-Rémy
dc.contributor.authorWu, Zhiguang
dc.contributor.authorDavies, Holly
dc.contributor.authorvan Diemen, Pauline M
dc.contributor.authorMilicic, Anita
dc.contributor.authorLa Ragione, Roberto M
dc.contributor.authorKaiser, Pete
dc.contributor.authorStevens, Mark P
dc.contributor.authorDziva, Francis
dc.date.accessioned2015-01-22T15:57:40Z
dc.date.available2015-01-22T15:57:40Z
dc.date.issued2015-01-23
dc.date.updated2015-01-22T15:57:41Z
dc.description.abstractAbstract Avian pathogenic Escherichia coli (APEC) infections are a serious impediment to sustainable poultry production worldwide. Licensed vaccines are available, but the immunological basis of protection is ill-defined and a need exists to extend cross-serotype efficacy. Here, we analysed innate and adaptive responses induced by commercial vaccines in turkeys. Both a live-attenuated APEC O78 and#916;aroA vaccine (Poulvacand#174; E. coli) and a formalin-inactivated APEC O78 bacterin conferred significant protection against homologous intra-airsac challenge in a model of acute colibacillosis. Analysis of expression levels of signature cytokine mRNAs indicated that both vaccines induced a predominantly Th2 response in the spleen. Both vaccines resulted in increased levels of serum O78-specific IgY detected by ELISA and significant splenocyte recall responses to soluble APEC antigens at post-vaccination and post-challenge periods. Supplementing a non-adjuvanted inactivated vaccine with Th2-biasing (Titermaxand#174; Gold or aluminium hydroxide) or Th1-biasing (CASAC or CpG motifs) adjuvants, suggested that Th2-biasing adjuvants may give more protection. However, all adjuvants tested augmented humoral responses and protection relative to controls. Our data highlight the importance of both cell-mediated and antibody responses in APEC vaccine-mediated protection toward the control of a key avian endemic disease.
dc.description.versionPeer Reviewed
dc.identifier.citationVeterinary Research. 2015 Jan 23;46(1):5
dc.identifier.urihttp://dx.doi.org/10.1186/s13567-014-0132-5
dc.identifier.urihttps://hdl.handle.net/2139/39475
dc.language.rfc3066en
dc.rights.holderJean-Rémy Sadeyen et al.; licensee BioMed Central Ltd.
dc.titleImmune responses associated with homologous protection conferred by commercial vaccines for control of avian pathogenic Escherichia coli in turkeys
dc.typeJournal Article

Files

Original bundle
Now showing 1 - 2 of 2
No Thumbnail Available
Name:
s13567-014-0132-5.xml
Size:
135.89 KB
Format:
Extensible Markup Language
Download
Thumbnail Image
Name:
s13567-014-0132-5.pdf
Size:
2.25 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

BioMed Central